Stocks · News reference
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.13) by 38.46 percent. This is a 14.29 percent increase over losses of $(0.21) per share
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-09-04 AccNo: 0001140361-26-035809 Size: 199 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 9.01: Financial Statements and Exhibits
HC Wainwright & Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and maintains $7 price target.
SEC.
On August 13, 2026, Lars Boesgaard submitted his resignation, effective as of September 12, 2026, as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of PDS Biotechnology Corporation